ArticleAnnals of hematology2025
Prognostic value of laboratory biomarkers for mortality risk stratification in thrombotic thrombocytopenic purpura.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to explore the relationship between laboratory indicators and short-term mortality risk in patients with thrombotic thrombocytopenic purpura (TTP) and to construct a risk stratification model. We retrospectively analyzed the clinical data of 106 patients with TTP admitted to Tongji Hospital between June 2016 and February 2025. Patients were grouped by 28-day survival: death (n = 45) and survival (n = 61). Prognosis-related indicators were identified using receiver operating characteristic (ROC) curves and logistic regression analyses. A mortality risk stratification model was established. To validate the stability of the model, 30 external cases of TTP (January 2022-December 2024) were collected. The levels of cardiac troponin I (cTnI), lactate dehydrogenase (LDH), blood urea nitrogen (BUN), and indirect bilirubin (IBIL) were significantly higher in the death group compared to those in the survival group. ROC analysis identified optimal mortality risk cutoffs: cTnI at 353.1 pg/mL (odds ratio [OR] = 4.778), LDH at 992 U/L (OR = 2.842), BUN at 10.9 mmol/L (OR = 5.527), and IBIL at 32.3 µmol/L (OR = 2.995). A subsequent 0-4 point risk stratification model demonstrated increasing mortality rates of 21.3% (0-1 point), 39.1% (2 points), 60.9% (3 points), and 92.3% (4 points). Each 1-point increase in the risk score was associated with a 2.324-fold rise in mortality risk (95% confidence interval 1.597-3.383). Internal and external validations confirmed the model's stability and strong prognostic performance in patients with TTP. The risk model incorporating cTnI, LDH, BUN, and IBIL levels effectively predicted short-term mortality in patients with TTP. Patients with a score of 3 or higher required close monitoring and aggressive therapeutic intervention to mitigate mortality risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.